HOME
>
臨床医学：内科
>
内科学一般
> 自家末梢血幹細胞移植マニュアル

自家末梢血幹細胞移植マニュアル

出版社：	日本医学館
著者：	池田和眞(編)
発行日：	2012-07-14
分野：	臨床医学：内科 > 内科学一般
ISBN：	9784890447527
電子書籍版：	2012-07-14 （第1版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

品切れ

4,400 円(税込)

電子書籍

章別単位で購入

ブラウザ、アプリ閲覧

2,200 円(税込)

購入する

商品紹介

岡山大学病院の移植病棟と輸血部のマニュアルをベースに作成したマニュアル。自家移植の概要から適応、幹細胞採取、保存、解凍の手順、移植後の合併症まで詳細に記載する。

目次

自家末梢血幹細胞移植マニュアル

―目次―

1．自家移植の概要
2．自家移植の適応
3．自己末梢血幹細胞採取
　　A. PBSCHのための化学療法
　　B. 採取のタイミング
　　C．Poor mobilizer
　　D. 末梢血管細胞採取（auto PBSCH）の実際
　　E. 副作用対策
　　F. 採取・保存の記録
4．末梢血管細胞の凍結・解凍
5．自家移植の実際
6．移植後合併症
　　A. 感染症・発熱時
　　B. 口腔粘膜傷害
　　C. 下痢
　　D．肝機能異常

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[1] 自家移植の概要

P.6 掲載の参考文献

1) Schriber J, Krishnan A. Forman S:Autologous transplantation for hematologic malignancies. Hematology, 5th edition. Churchill Livingstone, Philadelphia, 2009.

2) 原田実根:末梢血幹細胞移植の概要. 末梢血幹細胞移植の実際. 南江堂, 2001.

3) 日本造血細胞移植学会JSHCTデータセンター:平成21年度全国調査報告書. 2010.

[2] 自家移植の適応

P.21 掲載の参考文献

1) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329(14):987-994, 1993.

2) Philip T, Guglielmi C, Hagenbeek A et al.:Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapysensitive non-Hodgkin's lymphoma. N Engl J Med 333(23):1540-1545, 1995.

3) Haioun C, Lepage E, Gisselbrecht C et al.:Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive nonHodgkings lymphoma:updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de radulte. J Clin Oncol 15(3):1131-1137, 1997.

4) Smith SD, Bolwell BJ, Rybicki LA et al.:Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab. Bone Marrow Transplant 46(2):262-266, 2011.

5) Mac Manus MP, Hoppe RT:Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14(4):1282-1290, 1996.

6) Hiddemann W, Kneba M, Dreyling M et al.:Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725-3732, 2005.

7) Sebban C, Mounier N, Brousse N et al.:Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma:the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte(GELA). Blood 108(8):2540-2544, 2006.

8) Milligan DW, Ruiz De Elvira MC, Kolb HJ et al.:Secondary leukemia and myelodysplasia after autografting for lymphoma:results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Trasplantation. Br J Haematol 106(4):1020-1026, 1999.

9) Schouten HC, Qian W, Kvaloy S et al.:High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma:results from the randomized European CUP trial. J Clin Oncol 21(21):3918-3927, 2003.

10) Zucca E, Roggero E, Pinotti G et al.:Patterns of survival in mantle cell lymphoma. Ann Oncol 6(3):257-262, 1995.

11) Romaguera JE, Fayad L, Rodriguez MA et al.:High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013-7023, 2005.

12) Jermann M, Jost LM, Taverna C et al.:Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas:results of a phase II study. Ann Oncol 15(3) :511-516, 2004.

13) Geisler CH, Kolstad A, Laurell A et al.:Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7):2687-2693, 2008.

14) Linch DC, Winfield D, Goldstone AH et al.:Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease:results of a BNLI randomised trial. Lancet 341(8852):1051-1054, 1993.

15) Schmitz N, Pfistner B, Sextro M et al.:Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:a randomised trial. Lancet 359(9323):2065-2071, 2002.

16) Hasenclever D, Diehl V:Aprognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339(21):1506-1514, 1998.

17) Federico M, Bellei M, Brice P et al.:High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21(12):2320-2325, 2003.

18) Rodriguez J, Caballero MD, Gutierrez A et al.:High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma:the GELTAMO experience. Ann Oncol 14(12):1768-1775, 2003.

19) Mercadal S, Briones J, Xicoy B et al.:Intensive chemotherapy(high-dose CHOP/ESHAP regimen)followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19(5):958-963, 2008.

20) Reimer P, Rudiger T, Geissinger E et al.:Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas:results of a prospective multicenter study. J Clin Oncol 27(1):106-113, 2009.

21) Went P, Agostinelli C, Gallamini A et al.:Marker expression in peripheral T-cell lymphoma:aproposed clinical-pathologic prognostic score. J Clin Oncol 24(16):2472-2479, 2006.

22) Rodriguez J, Conde E, Gutierrez A et al.:The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL)in first complete remission:the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 18(4):652-657, 2007.

23) Kyriakou C, Canals C, Goldstone A et al.:High-dose therapy and autologous stemcell transplantation in angioimmunoblastic lymphoma:complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26(2):218-224, 2008.

24) Kyriakou C, Canals C, Finke J et al.:Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma:a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Onco127(24):3951-3958, 2009.

25) Deconinck E, Lamy T, Foussard C et al.:Autologous stem cell transplantation for anaplastic large-cell lymphomas:results of a prospective trial. Br J Haematol 1O9(4):736-742, 2000.

26) Zamkoff KW, Matulis MD, Mehta AC, Beaty MW, Hutchison RE, Gentile TC:Highdose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant 33(6):635-638, 2004.

27) Tallman MS:What is the role of arsenic in newly diagnosed API? Best Pract Res Clin Haematol 21(4):659-666, 2008.

28) Gorin NC, Labopin M, Frassoni F et al.:Identical outcolne after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21):a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 26(19) :3183-3188, 2008.

29) Kuwatsuka Y, Miyamura K, Suzuki R et al.:Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia:t(8;21)and inv(16)represent different clinical outcomes. Blood 113(9):2096-2103, 2009.

30) Paschka P, Marcucci G, Ruppert AS et al.:Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16)and t(8;21):a Cancer and Leukemia Group B Study. J Clin Oncol 24(24):3904-3911, 2006.

31) Miyamoto T:Autologous peripheral blood stem cell transplantation as a treatment choice for adult acute myelogenous leukemia. Rinsho Ketsueki 51(7):477-483, 2010.

32) Linker C:Autologous hematopoietic cell transplantation for acute lymphocytic leukemia. Thomas's 3rd ed Boston:Blackwell Science Inc, 2004:1055,

33) Bishop MR, Logan BR, Gandham S et al.:Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation:a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant 41(7):635-642, 2008.

34) de Witte T, Suciu S, Verhoef G et al.:Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes(MDSs)and acute myeloid leukemia following MDS. Blood 98(8):2326-2331, 2001.

35) Michallet M, Dreger P, Sutton L et al.:Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia:results of European intergroup randomized trial comparing autografting versus observation. Blood 117(5):1516-1521, 2011.

36) Huber S, Oelsner M, Decker T et al.:Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia, 25(5):838-847, 2011.

37) Attal M, Harousseau JL, StoPPa AM et al.:A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335(2):91-97, 1996.

38) Attal M, Harousseau JL, Facon T et al.:Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349(26):2495-2502, 2003.

39) Cavo M, Tosi P, Zamagni E et al.:Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25(17):2434-2441, 2007.

40) Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B:Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma i a systematic review and meta-analysis. J Natl Cancer lnst 101(2):100-106, 2009.

41) Garban F, Attal M, Michallet M et al.:Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft(IFM99-03 trial)with tandem autologous stem cell transplantation(IFM99-04 trial)in high-risk de novo multiple myeloma. Blood 107(9):3474-3480, 2006.

42) Motzer RJ, Nichols CJ, Margolin KA et al.:Phase In randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25(3):247-256, 2007.

43) Kondagunta GV, Bacik J, Sheinfeld J et al.:Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 25(1) :85-90, 2007.

44) Dispenzieri A, Kyle RA, Lacy MQ et al.:Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation:a case-control study. Blood 103(10):3960-3963, 2004.

45) Jaccard A, Moreau P, Leblond V et al.:High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357(11):1083-1093, 2007.

46) Hotte SJ, Smith AM, Bramwell VH, Howson-Jan K:High-Dose Chemotherapy Followed by Peripheral and/or Bone Marrow Stem Cell Transplant in Patients With Advanced Sarcoma : Experience of a Canadian Centre. Sarcoma 8(2～3):63-69, 2004.

47) Tack GJ, Wondergem MJ, Al-Toma A et al.:Auto-SCT in refractory celiac disease type n patients unresponsive to cladribine therapy. Bone Marrow Transplant 46(6) :840-846, 2011.

48) Shevchenko YL, Novik AA, Kuznetsov AN et al.:High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 36(8):922-928, 2008.

49) Burt RK, Traynor A, Statkute L et al.:Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 295(5):527-535, 2006.

[3] 自己末梢血幹細胞採取

P.42 掲載の参考文献

1) Dreger P, Kloss M, Petersen B et al.:Autologous progenitor cell transplantation:prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 86(10):3970-3978, 1995.

2) Boccadoro M, Palumbo A, Bringhen S et al.:Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 87(8):846-850, 2002.

3) Witzig TE, Geyer SM, Kurtin PJ et al.:Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma:a phase n trial in the North Central Cancer Treatment Group. Leuk Lymphoma 49(6):1074-1080, 2008.

4) Vose J, Sneller V:Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide(R-ICE)for relapsed non-Hodgkin's lymphoma. Ann Oncol 14(Suppl 1) :117-20, 2003.

5) Oki Y, Ogura M, Kato H et al.:Phase H study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci 99(1):179-184, 2008.

6) Nishimori H, Fujii N, Maeda Y et al.:Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma. Anticancer Res 29(5):1749-1754, 2009.

7) Reiser M, Josting A, Draube A et al.:Successful peripheral blood stem cell mobilization with etoposide(VP-16)in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant 23(12):1223-1228, 1999.

8) To LB, Shepperd KM, Haylock DN et al.:Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 18(5):442-447, 1990.

9) Haas R, Mohle R, Fruhauf S et al.:Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83(12):3787-3794, 1994.

10) Schwella N, Beyer J, Schwaner I et al.:Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 14(4):1114-1121, 1996.

11) Schots R, Van Riet I, Damiaens S et al.:The absolute number of circulating CD34+cells predicts the number of hematopoietic stem cells that can be collected by apheresis. Bone Marrow Transplant 17(4):509-515, 1996.

12) Elliott C, Samson DM, Armitage S et al.:When to harvest peripheral-blood stem cells after mobilization therapy:prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. J Clin Oncol 14(3):970-973, 1996.

13) Ikeda K, Kozuka T, Harada M:Factors for PBPC collection efficiency and collection predictors. Transfus Apher Sci 31(3):245-259, 2004.

14) Teshima T, Sunami K, Bessho A et al.:Circulating immature cell counts on the harvest day predict the yields of CD34+cells collected after granulocyte colony-stimulating factor plus chemotherapy-induced mobilization of peripheral blood stem cell. Blood 89(12):4660-4661, 1997.

15) Kozuka T, Ikeda K, Teshima T et al.:Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization. Transfusion 42(11):1514-1522, 2002.

16) Tjonnfjord GE, Steen R, Evensen SA, Thorsby E. Egeland T:Characterization of CD34+peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 84(8):2795-2801, 1994.

17) Grigg AP, Roberts AW, Raunow H et al.:Optimizing dose and scheduling of filgrastim(granulocyte colony-stimulating factor)for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 86(12):4437-4445, 1995.

18) Harada M, Nagafuji K, Fujisaki T et al.:G-CSF-induced mobilization of peripheral blood stem cells from healthy adults for allogeneic transplantation. J Hematother 5(1) :63-71, 1996.

19) Yano T, Katayama Y, Sunami K et al.:G-CSF-induced mobilization of peripheral blood stem cells for allografting:comparative study of daily single versus divided dose of G-CSF. Int J Hematol 66(2):169-178, 1997.

20) Stroncek DF, Clay ME, Petzoldt ML et al.:Treatment of normal individuals with granulocyte-colony-stimulating factor:donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 36(7):601-610, 1996.

21) Schriber J. Krishnan A, Forman S:Autologous transplantation for hematologic malignancies. Hematology, 5th ed. Churchill Livingstone, 2009.

22) Shepherd KM, Charles P, Sage RE et al.:Mobilization of haemopoietic stem cells by cyclophosphamide into the peripheral blood of patients with haematological malignancies. Clin Lab Haematol 13(1):25-32, 1991.

23) Fraipont V, Sautois B, Baudoux E et al.:Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+cells and/or CFU-GM with chemotherapy and G-CSF. Transfusion 40(3):339-347, 2000.

24) Weaver CH, Potz J, Redmond J et al.:Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+cell content. Bone Marrow Transplant 19(11):1103-1110, 1997.

25) 西森久和, 藤井敬子, 池田和真:患者からの末梢血幹細胞採取. 末梢血幹細胞採取と成分採血-医師と看護師によるアフェレーシスの理解と実践. 医薬ジャーナル, 2011.

[4] 末梢血幹細胞の凍結・解凍

P.54 掲載の参考文献

1) 日本輸血・細胞治療学会, 日本造血細胞移植学会:院内における血液細胞処理のための指針. 2010.

2) 片山義雄:末梢血幹細胞の凍結保存. 末梢血幹細胞移植の実際. 南江堂, 2001.

3) Makino S, Harada M, Akashi K et al.:A simplified method for cryopreservation of peripheral blood stem cells at-80 degrees C without rate-controlled freezing. Bone Marrow Transplant 8(4):239-244, 1991.

4) Rowley SD, Bensinger WI, Gooley TA, Buckner CD:Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 83(9):2731-2736, 1994.

5) 平松靖史, 角南一貴, 前田嘉信・他:末梢血幹細胞採取・保存の効率化の検討. 日本輸血学会雑誌 46(1):1-6, 2000.

6) Takaue Y, Abe T, Kawano Y et al.:Comparative analysis of engraftment after cryopreservation of peripheral blood stem cell autografts by controlled-versus uncontrolled-rate methods. Bone Marrow Transplant 13(6):801-804, 1994.

7) Katayama Y, Yano T, Bessho A et al.:The effects of a simplified method for cryopreservation and thawing procedures on peripheral blood stem cells. Bone Marrow Transplant 19(3):283-287, 1997.

[5] 自家移植の実際

P.83 掲載の参考文献

1) Sorror ML, Maris MB, Storb R et al.:Hematopoietic cell transplantation(HCT)-specific comorbidity index:a new tool for risk assessment before aliogeneic HCT. Blood 106(8):2912-2919, 2005,

2) Socie G, Salooja N, Cohen A et al.:Nonmalignant late effects after allogeneic stem cell transplantation. Blood 101(9):3373-3385, 2003.

3) Salooja N, Szydlo RM, Socie G et al.:Pregnancy outcomes after peripheral blood or bone marrow transplantation:a retrospective survey. Lancet 358(9278):271-276, 2001.

4) 日本造血細胞移植学会. 造血細胞移植ガイドライン-移植後早期の感染管理, 2000.

5) Eickhoff TC:Microbiological sampling. Hospitals 44(8):86-87, 1970.

6) AHA:Statement on microbiologic sampling in the hospital. Committee on Infection Within Hospitals, American Hospital Association. Hospitals 48(1):125-126, 1974.

7) Walsh TJ, Dixon DM:Nosocomial aspergillosis:environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol 5(2):131-142, 1989.

8) Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 33(2):139-144, 2001,

9) Kanda J, Ichinohe T, Saito T et al:Impact of discontinuing fluoroquinolone prophylaxis on early mortality after allogeneic marrow or peripheral blood SCT with myeloablative conditioning. Bone Marrow Transplant 45(8):1369-1371, 2010.

10) Gafter-Gvili A, Fraser A, Paul M, Leibovici L:Meta-analysis:antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142(12 Pt 1):979-995, 2005.

11) Gulati SC, Shank B, Black P et al.:Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 6(8):1303-1313, 1988.

12) Gralla RJ, Osoba D, Kris MG et al.:Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17(9):2971-2994, 1999.

13) Abbott B, lppoliti C, Hecth D, Bruton J, Whaley B, Champlin R:Granisetron(Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant 25(12):1279-1283, 2000.

14) 片山義雄:末梢血幹細胞の凍結保存. 末梢血幹細胞移植の実際, 南江堂, 2001.

15) Katayama Y, Yano T, Bessho A et al.:The effects of a simplified method for cryopreservation and thawing procedures on peripheral blood stem cells. Bone Marrow Transplant 19(3):283-287, 1997.

16) Ho VT, Cutler C, Carter S et al.:Blood and marrow transplant clinical trials network toxicity committee consensus summary:thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11(8):571-575, 2005.

17) Ruutu T, Barosi G, Benjamin RJ et al.:Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy:results of a consensus process by an International Working Group. Haematologica 92(1):95-100, 2007.

[6] 移植後合併症

P.98 掲載の参考文献

1) Soga Y, Sugiura Y, Takahashi K et al.:Progress of oral care and reduction of oral mucositis-a pilot study in a hematopoietic stem cell transplantation ward. Support Care Cancer 19(2):303-307, 2010.

2) Sugiura Y, Soga Y, Tanimoto I et al.:Antimicrobial effects of the saliva substitute, oralbalance, against microorganisms from oral mucosa in the hematopoietic cell transplantation period. Support Care Cancer 16(4):421-424, 2008.

3) NCI-PDQ. Cancer Information Summaries:Supportive Care, Oral Complications of Chemotherapy and Hcad/Ncck Radiation, 2011.

4) Kumar S, DeLeve LD, Kamath PS, Tefferi A:Hepatic veno-occlusive disease (sinusoidal obstruction syndrome)after hematopoietic stem cell transplantation. Mayo Clin Proc 78(5):589-598, 2003.

5) Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB:Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy:incidence, risk factors, and outcome. Biol Blood Marrow Transplant 5(5):306-315, 1999.

6) Ho VT, Revta C, Richardson PG:Hepatic veno-occlusive disease after hemato-poietic stem cell transplantation:update on defibrotide and other current investigational therapies. Bone Marrow Transplant 41(3):229-237, 2008.

7) Schriber J, Krishnan A, Forman S:Autologous transplantation for hematologic malignancies. Hematology, 5th edition. Churchill Livingstone, Philadelphia, 2009.

書評

書評を投稿する

最近チェックした商品履歴

Loading...